Tag Archives: health

Hot Investor Mandate: USA-Based Seed Fund Invests in Software-Enabled Health Technologies, With Expanding Interests in Traditional Life Science Companies 

19 Aug

A US-based advisory group also manages a seed fund making investments into healthcare companies. Traditionally, the firm has strong expertise in enterprise software and is most interested in healthcare companies that have a software component (such as EHR/EMR integration), monitoring technologies, and early-stage detection devices and diagnostics. The firm is also starting to explore opportunities in traditional biotech investments and drug discovery-enabling tools. The firm considers global opportunities. 

The firm is currently exploring opportunities in traditional life sciences (therapeutics, diagnostics) as well as software or technology-enabled healthcare companies. While the firm is opportunistic regarding specific technologies and disease areas, the firm generally does not invest in companies that require FDA regulatory approval. 

The firm does not have specific company or management team requirements and has no preference on leading or co-investing. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Cross-Border Investment Firm Seeks Therapeutics and Medical Technologies, Investing from Seed to Pre-IPO

19 Aug

The firm is an investment firm based in Shanghai, China. The firm manages 30 billion RMB and invests in fund of funds as well as direct equity investments. The firm invests across multiple sectors, with life science and healthcare being one of its primary focuses. The sweet spot starts from pre-A rounds, and the firm can invest anywhere up to pre-IPO stages. While the firm primarily focuses on opportunities in China, it is open to global opportunities, particularly those interested in soft-landing in China/Shanghai or with a China angle. The firm is open to both leading investments and co-investing. 

Within life science and healthcare, the firm is most interested in biotech therapeutics and medical technologies. For therapeutics, the firm is open to exploring various modalities (excluding mRNA) and indications such as CNS and oncology. For medical devices, the firm seeks innovative technologies, including invasive technologies, imaging devices, and brain-computer interfaces, rather than non-innovative solutions such as consumables. 

The firm does not have specific requirements for a company’s founding team but prefers companies interested in coming to Shanghai/China. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Multi-Stage Generalist Seed Fund Invests Globally in Value-Based Life Sciences and Healthcare Companies

19 Aug

A multi-stage generalist venture capital investor can write flexible check sizes typically up to $300,000 for early-stage opportunities and can participate in follow-on investments. The firm is open to global companies. 

The firm has invested in digital health, techbio, value-based healthcare, and life sciences. The firm is disease-agnostic. Notable investments in healthcare have included digital health platforms, pharmacy solutions, clinical trial innovation, and biotech companies. 

The firm does not have specific company or management team requirements. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Pullan’s Pieces #4 – January – A Corner on Market Sentiments – Seed to Series A

19 Aug

As the saying goes, “What’s in a name?  That which we call a Series A by any other name would smell as sweet.”  Er… something like that, right? Hmmm, maybe it went a little bit differently.

But whatever it be, or not to be😊, the Seed Round is the new Series A. Clearly. I think we’ve all felt it for sometime but the data is in and the good ‘ole Series A just don’t buy what it used to.  Nahhh… the Seed round does that, and it may buy more (equity) than it used to as a Series A (more data hunting and crunching required but one gets a sense that the venture capitalists are, well, capitalizing).

Labiotech does a really nice job collecting and summarizing a variety of topics related to financings and dealmaking in the biotech sector and the 2024 breakdown of funding offers the following approximations (roughly, with some rounding made by this author):

The internal breakdowns for amounts invested look like this:

Readers of this corner will know that we keep a close eye on the XBI

As usual, the outliers can skew the numbers (more on this in a moment) but the median amounts invested into these rounds puh-rihhhty much drive the nail in the coffin of the old thinking about Series dynamics. This data could be charted in another way in which an inverted bell curve would appear and a GAPING hole between $20M and $50M would stare back at you.  Think about that for a moment… if you can’t get to value inflection for ~$15-20M, you better be raising $60-75M and have multiple reasons to do so as a cursory view of the companies listed in the dataset further indicates that the lower outliers (sub-median) on the Series A were generally geared for “finding out” about a single asset in the clinic.

Back to that previously mentioned outlier that can skew the averages… it also happens to bring even more of a spotlight to those famed words from Shakespeare which began this Corner on Market Sentiments.  One of the companies in the 2024 data set raised a whopping $100,000,000 … as a Seed Round!!  Indeed, a rose by any other name…

Tags: , , , , , , , , , , , , , , , , , , , , , , ,

Investing in Early-Stage Diagnostics Innovation 

12 Aug

By Joey Wong, Director of Investor Research, Hong Kong BD, LSN

Joey-New-Headshot

Diagnostics are becoming a cornerstone of modern healthcare, driving earlier detection, more precise treatments, and improved patient outcomes. From cutting-edge sequencing technologies and liquid biopsies to AI-driven tools and digital platforms, diagnostics are shaping a more preventative and personalized future for medicine.

RESI Boston will feature a Diagnostics Panel. This 50-minute panel will bring together leading investors and strategic partners who focus on early-stage diagnostics innovation. Panelists will discuss what makes a diagnostic technology attractive from both a clinical and commercial perspective, how they evaluate regulatory and reimbursement potential, and the areas where they see the most pressing unmet needs. From seed-stage investors to growth-equity leaders, this year’s panel will feature a range of investment perspectives. With representation from venture capital, strategic investors, and international funds, attendees will gain a well-rounded view of the current diagnostics investment landscape.

For founders developing solutions in oncology, infectious disease, chronic conditions, or personalized medicine, this session offers actionable guidance on securing funding, gaining market traction, and building successful partnerships. Expect practical insights on differentiation, positioning, and scaling impactful innovations in a competitive and fast-evolving space.

John-Tremblay Navin-Govind Anula-Jayasuriya
John Tremblay
Investor
Launchpad Venture Group
(Moderator)		 Navin Govind
Partner
Evidence Ventures		 Anula Jayasuriya
Co-Founder and Partner
Kidron Capital
Chris-Murray Mike-Thoma Chensu-Wang
Chris Murray
Principal
MVM Life Science Partners		 Mike Thomas
Managing Partner
Bold Brain Capital		 Chensu Wang
Investment Manager
Yonjin Venture

Don’t miss this opportunity to connect with investors and industry leaders shaping the future of diagnostics. Register now for RESI Boston this September and take the next step in advancing your diagnostic innovation.

Tags: , , , , ,

Hot Investor Mandate: VC Managing Multiple USD Funds Invests from Seed to Pre-IPO Stage Across Novel Therapeutics and AI-Driven Healthcare, With Focus on Companies With China Angle 

12 Aug

A China-based venture capital investor manages seven USD funds with limited partners from prestigious academic institutions and hospital systems in the United States. The firm is capable of investing at any stage, from seed to pre-IPO. While the firm manages USD funds, it is rooted in China and is particularly interested in opportunities with a China angle or involving Asian founders. 

The firm has previously invested at the intersection of AI and healthcare, such as AI-driven drug discovery, diagnostics, and imaging, but has broadened its scope to include therapeutics. The firm is particularly interested in novel modalities, including drug conjugates, radiopharmaceuticals, and cell and gene therapies. The firm is open to various indications, prioritizing those with considerable market potential, such as oncology, immunology, CNS, pain management, and kidney diseases. In terms of development phases, the firm prefers companies from IND to clinical phases but is willing to consider companies in the PCC phase at the earliest. 

The firm prefers companies with strong management teams, particularly those with industry experience in pharma or biotech. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: US Seed and Series A Investment Firm Seeks New Opportunities in Therapeutics, Medical Devices, Diagnostics, Digital Health

12 Aug

The firm is a venture capital investor headquartered in the US. The firm is currently investing from its third fund and allocates half of its capital into life science investments. The firm invests in Seed and Series A stages, with a typical check size of $1 million and up to $3 million in total after follow-on investments. The firm invests in four to five new companies each year and focuses on opportunities within the United States. 

The firm invests primarily in therapeutics and is also open to medical devices, molecular-based diagnostics, and digital health. The firm is indication- and modality-agnostic. 

The firm has no specific management team requirements. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

← Older Entries
Newer Entries →